Screener
Zevra Therapeutics, Inc. ZVRA EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Zevra Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s EBITDA margin?
- Zevra Therapeutics, Inc. (ZVRA) reported EBITDA margin of 65.5% in Q2 2026.
- How has Zevra Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Zevra Therapeutics, Inc.'s EBITDA margin increased by 136.1% year-over-year, from -181.5% to 65.5%.
- What is the long-term trend for Zevra Therapeutics, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s EBITDA margin has grown at a 4.6% compound annual growth rate (CAGR), from -40.2% to -50.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Zevra Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude